NAS100 29,544 +0.21% S&P 7,719 −0.38% GOLD $4,477 −0.32% BTC $79,689 −1.95% VIX 14.53 +1.47% live tape · as of 23:26 UTC · 4 Sep
Vol. II · No. 249Sunday, 6 September 2026
TTitan Protect

Live Model Portfolio

Titan Gems

The names our ethical framework flagged before the crowd, each with the date we called it, the financials and ethics behind it, the upside we see, and the live result since. Not a tip sheet. A dated, honest record you can watch unfold.

Updated 2026-09-04 · Analysis, not financial advice.

Case Studies · real, dated positions

Live positions we entered and are tracking to the day.

DLO · dLocal Limited ✓ Ethical PASS
accumulation · STRONG OPPORTUNITY · $4.22bn
flagged 2026-07-01 @ $12.25
now $15.52   +26.7%

Upside

Target range
$15.0 – $21.0 (avg $18.0)
Implied +16.0% to average
Our fair value $21.0 · 33% discount

Financials

Revenue growth 55.8%
Fwd P/E 12.7
Profit margin 15.0%
Debt/Equity 12.5

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 33% discount to our $21.00 fair value, strong competitive moat, 56% revenue growth, and clears all 5 of our ethical screens. Full analysis →

CRMD · CorMedix Inc. ✓ Ethical PASS
markup · STRONG OPPORTUNITY · $0.64bn
flagged 2026-07-01 @ $8.36
now $8.43   +0.8%

Upside

Target range
$13.0 – $19.0 (avg $15.0)
Implied +77.9% to average
Our fair value $11.4 · 34% discount

Financials

Revenue growth 157%
Fwd P/E 23.5
Profit margin 40.5%
Debt/Equity 32.0

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 34% discount to our $11.35 fair value, strong competitive moat, 157% revenue growth, and clears all 5 of our ethical screens. Full analysis →

Hidden Gems · small-caps our screens rate now

Sub-$1bn names, ethically clean, flagged at today's price.

ETON · Eton Pharmaceuticals, Inc. ✓ Ethical PASS
markup · OPPORTUNITY · $1.76bn
flagged 2026-07-18 @ $42.32
now $58.45   +38.1%

Upside

Target range
$68.0 – $76.0 (avg $70.0)
Implied +19.8% to average
Our fair value $63.4 · 3% discount

Financials

Revenue growth 98.6%
Fwd P/E 23.8
Profit margin 12.0%
Debt/Equity 62.7

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 3% discount to our $63.38 fair value, weak competitive moat, 99% revenue growth, and clears all 5 of our ethical screens. Full analysis →

GAU · Galiano Gold Inc. ✓ Ethical PASS
accumulation · OPPORTUNITY · $0.58bn
flagged 2026-07-18 @ $1.72
now $2.27   +32.0%

Upside

Target range
$4.3 – $4.3 (avg $4.3)
Implied +87.2% to average
Our fair value $3.0 · 35% discount

Financials

Revenue growth 117%
Fwd P/E 3.0
Profit margin 13.7%
Debt/Equity 22.5

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 35% discount to our $2.98 fair value, weak competitive moat, 117% revenue growth, and clears all 5 of our ethical screens. Full analysis →

KMDA · Kamada Ltd. ✓ Ethical PASS
markup · OPPORTUNITY · $0.46bn
flagged 2026-07-18 @ $7.05
now $8.54   +21.1%

Upside

Target range
$11.0 – $15.0 (avg $13.0)
Implied +52.2% to average
Our fair value $13.1 · 66% discount

Financials

Revenue growth 2.8%
Fwd P/E 13.2
Profit margin 11.2%
Debt/Equity 4.5

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 66% discount to our $13.06 fair value, weak competitive moat, 3% revenue growth, and clears all 5 of our ethical screens. Full analysis →

FENC · Fennec Pharmaceuticals Inc. ✓ Ethical PASS
markup · OPPORTUNITY · $0.42bn
flagged 2026-07-18 @ $10.50
now $12.39   +18.0%

Upside

Target range
$16.0 – $20.0 (avg $18.0)
Implied +45.3% to average
Our fair value $19.5 · 64% discount

Financials

Revenue growth 85.2%
Fwd P/E 12.5
Profit margin -5.5%
Debt/Equity

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 64% discount to our $19.47 fair value, weak competitive moat, 85% revenue growth, and clears all 5 of our ethical screens. Full analysis →

KGEI · Kolibri Global Energy Inc. ✓ Ethical PASS
accumulation · OPPORTUNITY · $0.22bn
flagged 2026-07-18 @ $5.23
now $6.15   +17.6%

Upside

Target range
$8.0 – $8.0 (avg $8.0)
Implied +30.1% to average
Our fair value $6.7 · 11% discount

Financials

Revenue growth 103%
Fwd P/E 9.4
Profit margin 26.9%
Debt/Equity 20.8

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 11% discount to our $6.70 fair value, weak competitive moat, 103% revenue growth, and clears all 5 of our ethical screens. Full analysis →

ABUS · Arbutus Biopharma Corporation ✓ Ethical PASS
accumulation · OPPORTUNITY · $0.99bn
flagged 2026-07-18 @ $4.56
now $5.15   +12.9%

Upside

Target range
$5.5 – $5.5 (avg $5.5)
Implied +7.3% to average
Our fair value $5.5 · 11% discount

Financials

Revenue growth -90.6%
Fwd P/E -30.1
Profit margin 84.2%
Debt/Equity 1.4

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 11% discount to our $5.53 fair value, and clears all 5 of our ethical screens. Full analysis →

EPSN · Epsilon Energy Ltd. ✓ Ethical PASS
markup · OPPORTUNITY · $0.17bn
flagged 2026-07-18 @ $5.52
now $6.18   +12.0%

Upside

Limited analyst coverage: see full analysis.

Financials

Revenue growth 57.1%
Fwd P/E 15.1
Profit margin -5.2%
Debt/Equity 31.5

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It weak competitive moat, 57% revenue growth, and clears all 5 of our ethical screens. Full analysis →

LIEN · Chicago Atlantic BDC, Inc.
accumulation · STRONG OPPORTUNITY · $0.22bn
flagged 2026-07-18 @ $9.73
now $10.32   +6.1%

Upside

Target range
$11.0 – $11.0 (avg $11.0)
Implied +6.6% to average
Our fair value $11.0 · 13% discount

Financials

Revenue growth 40.1%
Fwd P/E 5.8
Profit margin 57.9%
Debt/Equity 17.9

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 13% discount to our $11.00 fair value, moderate competitive moat, 40% revenue growth, and clears all 5 of our ethical screens. Full analysis →

CURI · CuriosityStream Inc. ✓ Ethical PASS
markup · OPPORTUNITY · $0.17bn
flagged 2026-07-18 @ $2.56
now $2.71   +5.9%

Upside

Target range
$5.0 – $6.0 (avg $5.0)
Implied +84.5% to average
Our fair value $5.8 · 100% discount

Financials

Revenue growth 22.3%
Fwd P/E 9.4
Profit margin 0.0%
Debt/Equity 8.9

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 100% discount to our $5.84 fair value, weak competitive moat, 22% revenue growth, and clears all 5 of our ethical screens. Full analysis →

NEXN · Nexxen International Ltd. ✓ Ethical PASS
accumulation · OPPORTUNITY · $0.56bn
flagged 2026-07-18 @ $10.16
now $9.56   -5.9%

Upside

Target range
$12.0 – $25.4 (avg $13.0)
Implied +36.0% to average
Our fair value $16.3 · 62% discount

Financials

Revenue growth 10.5%
Fwd P/E 8.1
Profit margin 3.4%
Debt/Equity 7.7

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 62% discount to our $16.25 fair value, weak competitive moat, 11% revenue growth, and clears all 5 of our ethical screens. Full analysis →

HIT · Health In Tech, Inc. ✓ Ethical PASS
markdown · OPPORTUNITY · $0.07bn
flagged 2026-07-18 @ $1.13
now $0.98   -13.3%

Upside

Target range
$3.0 – $4.1 (avg $4.0)
Implied +308.2% to average
Our fair value $0.5

Financials

Revenue growth -13.5%
Fwd P/E 25.8
Profit margin -12.0%
Debt/Equity 0.5

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It weak competitive moat, and clears all 5 of our ethical screens. Full analysis →

GNSS · Genasys Inc. ✓ Ethical PASS
distribution · OPPORTUNITY · $0.08bn
flagged 2026-07-18 @ $1.72
now $1.45   -15.7%

Upside

Target range
$3.0 – $6.0 (avg $3.6)
Implied +148.3% to average
Our fair value $2.3 · 26% discount

Financials

Revenue growth -26.0%
Fwd P/E 16.0
Profit margin -10.9%
Debt/Equity

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 26% discount to our $2.32 fair value, weak competitive moat, and clears all 5 of our ethical screens. Full analysis →

LWAY · Lifeway Foods, Inc. ✓ Ethical PASS
distribution · OPPORTUNITY · $0.38bn
flagged 2026-07-18 @ $31.95
now $25.01   -21.7%

Upside

Target range
$34.0 – $35.0 (avg $34.5)
Implied +37.9% to average
Our fair value $31.0 · 24% discount

Financials

Revenue growth 24.1%
Fwd P/E 18.3
Profit margin 4.5%
Debt/Equity 26.6

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 24% discount to our $30.95 fair value, moderate competitive moat, 24% revenue growth, and clears all 5 of our ethical screens. Full analysis →

AMPG · AmpliTech Group, Inc. ✓ Ethical PASS
distribution · OPPORTUNITY · $0.11bn
flagged 2026-07-18 @ $6.64
now $3.37   -49.2%

Upside

Target range
$7.0 – $7.0 (avg $7.0)
Implied +107.7% to average
Our fair value $5.9 · 66% discount

Financials

Revenue growth -26.8%
Fwd P/E 6.6
Profit margin -33.4%
Debt/Equity 8.4

Ethics

Business activity
Debt ratio
Liquidity
Receivables
Revenue purity
Why it makes the list

It trades at a 66% discount to our $5.93 fair value, weak competitive moat, and clears all 5 of our ethical screens. Full analysis →

Watch the gems the crowd hasn't found yet

Members build and monitor their own portfolio from these, each position carrying our ethical verdict and framework read.

Join Titan Protect

Titan Gems is a model portfolio for illustration and analysis. It is not financial advice, not a recommendation to buy or sell, and not a personalised portfolio. Target ranges reflect third-party analyst estimates; our fair value and ethical screening reflect our own methodology. "Flagged" dates and prices are recorded when a name enters the list and are never edited. Past performance does not guarantee future results. Always do your own research and manage your risk.

Get our weekly market brief free.